Lucentis (Ranibizumab) for Eales' Disease

Summary

The primary objective of this protocol is to look at whether Lucentis (ranibizumab) is safe and effective when used for macular edema (retinal swelling) due to Eales' disease. The secondary objective is to see if macular edema comes back within three months after the last dose of study drug is given.

Timeline

Start

2006-10

Primary completion

2009-04

Completion

2009-04

Publications

• Results Gupta SR, Flaxel CJ. The use of a vascular endothelial growth factor inhibitor (ranibizumab) in macular edema due to eales disease. Retin Cases Brief Rep. 2012 Winter;6(1):122-4. doi: 10.1097/ICB.0b013e31821608e8.

Drugs

Indications